Pour les patients symptomatiques intolérants aux statines: un anticorps monoclonal

"Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lipoprotein (LDL) receptors, promoting their degradation and increasing LDL cholesterol levels. In phase 1 studies, a human monoclonal antibody to PCSK9, AMG145, was well tolerated and reduced LDL cholesterol levels."


http://jama.jamanetwork.com/article.aspx?articleid=1389227